A modified zeolite catalyst composition is disclosed formed from a zeolite, alumina binder, and matrix. The modified zeolite catalyst composition may contain fluorine. Also disclosed, are methods for the preparation of pyridine and/or its alkylpyridine derivatives in high yield utilizing the modified zeolite catalyst composition.

A modified zeolite catalyst composition is disclosed formed from a zeolite, alumina binder, and matrix. The modified zeolite catalyst composition may contain fluorine. Also disclosed, are methods for the preparation of pyridine and/or its alkylpyridine derivatives in high yield utilizing the modified zeolite catalyst composition.

A method for separating a homogeneous catalyst from a solution includes forming a host-guest compound between a first isomer of the catalyst and inclusion compound in the solution and isolating the host-guest compound from the solution. The catalyst may be released from the inclusion compound by converting the first isomer of the catalyst to a second isomer of the catalyst.

A method for separating a homogeneous catalyst from a solution includes forming a host-guest compound between a first isomer of the catalyst and inclusion compound in the solution and isolating the host-guest compound from the solution. The catalyst may be released from the inclusion compound by converting the first isomer of the catalyst to a second isomer of the catalyst.

Enantioselective syntheses of cis- and trans-bicyclic dihydropyran compounds, and other intermediates, en route to heteroyohimbine alkaloids.

Enantioselective syntheses of cis- and trans-bicyclic dihydropyran compounds, and other intermediates, en route to heteroyohimbine alkaloids.

The present invention relates to certain pharmaceutically acceptable salts of (S)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (S)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl) phenyl)piperidine and specific polymorphs thereof. More particularly, the present invention relates to the compounds of Formula (VI) as well as chemical routes for their manufacture.

The present invention relates to certain pharmaceutically acceptable salts of (S)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (S)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl) phenyl)piperidine and specific polymorphs thereof. More particularly, the present invention relates to the compounds of Formula (VI) as well as chemical routes for their manufacture.

The present invention relates to a process for preparing N,N-bis(2,2,6,6-tetramethylpiperidin-4-yl)hexane-1,6-diamine. The present invention further relates to the use of N,N-bis(2,2,6,6-tetramethylpiperidin-4-yl)hexane-1,6-diamine to prepare poly[[6-[(1,1,3,3-tetramethylbutyl)amino]-s-triazine-2,4-diyl]-[(2,2,6,6-tetramethyl-4-piperidyl)imino]-hexamethylene-[(2,2,6,6-tetramethyl-4-piperidyl)imino], reaction material of 1,6-hexanediamine, N,N-bis (2,2,6,6-tetramethyl-4-piperidine-yl),2,4,6-trichloro-1, 3,5-triazine,N-butyl-1-butylamine, and N-butyl-2,2,6,6-tetramethyl-4-piperidineamine, N,N-bis(2,2,6,6-tetramethyl-4-piperidyl)-N,N-diformylhexamethylenediamine, and 1,6-Hexanediamine, N,N-bis(2,2,6,6-tetramethyl-4-piperidinyl)-, polymer with 2,4-dichloro-6-(4-morpholinyl)-1,3,5-triazine.

The present invention relates to a process for preparing N,N-bis(2,2,6,6-tetramethylpiperidin-4-yl)hexane-1,6-diamine. The present invention further relates to the use of N,N-bis(2,2,6,6-tetramethylpiperidin-4-yl)hexane-1,6-diamine to prepare poly[[6-[(1,1,3,3-tetramethylbutyl)amino]-s-triazine-2,4-diyl]-[(2,2,6,6-tetramethyl-4-piperidyl)imino]-hexamethylene-[(2,2,6,6-tetramethyl-4-piperidyl)imino], reaction material of 1,6-hexanediamine, N,N-bis (2,2,6,6-tetramethyl-4-piperidine-yl),2,4,6-trichloro-1, 3,5-triazine,N-butyl-1-butylamine, and N-butyl-2,2,6,6-tetramethyl-4-piperidineamine, N,N-bis(2,2,6,6-tetramethyl-4-piperidyl)-N,N-diformylhexamethylenediamine, and 1,6-Hexanediamine, N,N-bis(2,2,6,6-tetramethyl-4-piperidinyl)-, polymer with 2,4-dichloro-6-(4-morpholinyl)-1,3,5-triazine.